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Abstract The increase of cancer specificity and efficacy
of anti-tumoral agents are prime strategies to overcome the
deleterious side effects associated with anti-cancer treat-
ments. We described earlier a cell-permeable protease-
resistant peptide derived from the p120 RasGAP protein,
called TAT-RasGAP317–326, as being an efficient tumor-
specific sensitizer to apoptosis induced by genotoxins
in vitro and in vivo. Bcl-2 family members regulate the
intrinsic apoptotic response and as such could be targeted
by TAT-RasGAP317–326. Our results indicate that the
RasGAP-derived peptide increases cisplatin-induced Bax
activation. We found no evidence, using in particular
knock-out cells, of an involvement of other Bcl-2 family
proteins in the tumor-specific sensitization activity of TAT-
RasGAP317–326. The absence of Bax and Bak in mouse
embryonic fibroblasts rendered them resistant to cisplatin-
induced apoptosis and consequently to the sensitizing
action of the RasGAP-derived peptide. Surprisingly, in the
HCT116 colon carcinoma cell line, the absence of Bax and
Bak did not prevent cisplatin-induced apoptosis and the
ability of TAT-RasGAP317–326 to augment this response.
Our study also revealed that p53, while required for an
efficient genotoxin-induced apoptotic response, is dis-
pensable for the ability of the RasGAP-derived peptide to
improve the capacity of genotoxins to decrease long-term
survival of cancer cells. Hence, even though genotoxin-
induced Bax activity can be increased by TAT-Ras-
GAP317–326, the sensitizing activity of the RasGAP-derived
peptide can operate in the absence of a functional mito-
chondrial intrinsic death pathway.
Keywords RasGAP  Tumor sensitization  Bcl-2
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Introduction
The modulation of tumor cell sensitivity to genotoxic
agents is one major issue in anticancer research [1]. The
development of small molecules able to selectively increase
the susceptibility of cancer cells to genotoxin-induced cell
death would ameliorate the efficacy of chemotherapy and
offer substantial benefits to individuals with cancer. A few
compounds have been demonstrated to act as tumor sensi-
tizers. These compounds are generally devoid, on their own,
of any cytostatic or cytolytic effect on cells but they
increase the ability of known anti-cancer agents to kill
tumor cells. ADD70 corresponds to a fragment of the
apoptosis-inducing factor (AIF) protein that binds the
Hsp70 heat shock protein [2]. When expressed in colon
carcinoma and lymphoma, ADD70 sensitizes them to cis-
platin [3]. However, ADD70 does not have the ability to
enter cells and cannot therefore be used as is as a tumor
sensitizer in vivo. SmacN7 is a short seven amino acid long
peptide derived from Smac/Diablo, a protein released by the
mitochondria in response to apoptotic stimuli that inhibits
inhibitor of apoptosis proteins (IAPs) and hence favors the
apoptotic process [4]. While apparently not inducing
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apoptosis of cancer cells by itself, a cell-permeable version
of SmacN7 potentiates the action of genotoxins [5–7].
Our laboratory has developed an anti-tumor peptide that
selectively sensitizes several cancer cell lines, but not non-
cancer cell lines, to genotoxin-induced apoptosis [8]. The
anti-tumor activity of this peptide is carried by a ten-amino
acid long sequence derived from the SH3 domain of p120
RasGAP. This sequence corresponds to residues 317–326
of the RasGAP protein [8]. The RasGAP317–326 peptide
was made cell permeable by hooking it to a short sequence
of the HIV TAT protein (residues 48–57) that allows
polypeptides to penetrate cells [9], resulting in the so-
called TAT-RasGAP317–326 peptide. This compound by
itself, does not affect cell viability [8]. The RasGAP-
derived peptide is also capable of increasing the anti-cancer
activity of cisplatin and doxorubicin against human tumor
xenografts [10] and to augment the killing efficiency of
photodynamic therapy in mesothelioma cells [11].
Recently, TAT-RasGAP317–326 was shown to inhibit
migration and invasion in vitro, indicating that it has the
potential to function as an anti-metastatic compound [12].
Genotoxins are DNA-damaging substances that exert
their anti-tumor activity by causing apoptosis in cancer
cells mainly through the mitochondrial pathway [13–15].
The genotoxin-induced DNA damage response is orches-
trated by a series of kinases (e.g. the ataxia-telangiectasia
mutated, ATM) that sense the extent of the damage and
activate downstream effectors [16, 17]. One of the key
DNA damage response effector is p53, a transcription
factor that regulates the expression of genes involved in
cell cycle arrest (e.g. p21) and apoptosis (e.g. Puma and
Bax) [18]. Puma and Bax both belong to the Bcl-2 family
that tightly controls, directly or indirectly, the release of
pro-apoptotic molecules from the mitochondria [19].
Members of this family share up to four BH (Bcl-2
Homology) domains and are conventionally subdivided
into three groups on the basis of their pro- or anti-apoptotic
activity and the BH domains they contain. Anti-apoptotic
players (Bcl-2, Bcl-XL, Bcl-w, Mcl-1 and A1) and pro-
apoptotic players (Bax, Bak and Bok) possess four BH
domains, whereas the pro-apoptotic BH3-only proteins
(Bid, Bim, Bad, Bmf, Bik, Noxa, Puma and Hrk) display
only the BH3 domain [20]. When the balance between pro-
and anti-apoptotic members of this family tips in favor of
the former, mitochondrial membrane integrity is lost,
cytochrome c is released in a Bax/Bak-dependent manner
and this leads to caspase activation and apoptosis [21].
There are currently two main models describing how these
proteins determine cell fate. These models are not neces-
sarily mutually exclusive [22–24]. According to the ‘indi-
rect model’, pro-apoptotic Bax and Bak are neutralized by
anti-apoptotic proteins (e.g. Bcl-2) under normal condi-
tions. When cells are subjected to apoptotic insults, BH3-
only proteins displace Bax and Bak from their guardians
allowing them to oligomerize in the outer mitochondrial
membrane, leading to cytochrome c release and cell death
[25]. Conversely, the ‘direct model’ supports a direct Bax/
Bak activating role for a subgroup of the BH3-only
members (tBid, Bim and Puma) called the ‘activators’. In
basal conditions, these are sequestered by the anti-apop-
totic proteins but in response to apoptotic stimuli they are
displaced by the BH3-only ‘sensitizer’ members (e.g. Bad
and Noxa). The freed ‘activators’ can then promote the
oligomerization of Bax and Bak [26, 27].
We showed earlier that TAT-RasGAP317–326 does not
modulate MAPK signaling pathways (p38, ERK and JNK),
NF-jB transcriptional activity or Akt protein levels and
phosphorylation status [8, 28]. Here we show that the
activity of Bax can be modulated by TAT-RasGAP317–326
in the context of tumor cells sensitization to genotoxin-
induced apoptosis. Our data indicate however that Bcl-2
family members, including Bax and Bak, are dispensable
for the capacity of the peptide to increase forms of death
distinct from the classical mitochondrial apoptotic pathway.
Materials and methods
Chemicals
Cisplatin (Sigma, ref. no. P4394) was dissolved in water at a
1 mg/ml concentration and stored at -80 C. TNFa (Pierce,
ref. no. RTNFA10) was dissolved in water at a concentration
of 10 lg/ml, aliquoted and stored at -80 C. Cycloheximide
(CHX) (Sigma, ref. no. C7698) was dissolved in methanol at
20 mg/mL and stored at -20 C. Paraformaldehyde (PFA)
and HCl were from Acros (ref. no. 30525-89-4 and 7647-01-
0, respectively). Hoechst 33342 (Molecular Probe, Invitro-
gen, ref. no. H21492) was prepared as a 10 mg/ml water
solution, stored at 4 C and used at a final concentration of
10 lg/ml. The pan-caspase inhibitor MX1013 was a kind gift
from Maxim Pharmaceuticals (San Diego, CA). Tris base [2-
Amino-2-(hydroxymethyl)-1,3-propanediol], sodium dode-
cyl sulfate (SDS), mannitol, sucrose and trichloroacetic acid
were from Sigma (ref. no. T1503, L4390, M4125, S0389 and
T9159 respectively). HEPES [4-(2-hydroxyethyl)-1-piper-
azineethanesulfonic acid] and polyoxyethylene (20) sorbitan
monolaurate (Tween 20) were from AppliChem (ref. no.
A3724 and 1873580, respectively). NaCl, EGTA [ethylene-
bis(oxyethylenenitrilo)tetraacetic acid] and bromophenol
blue were from Acros (ref. no. 7647-14-5, 67-42-5, and
115-39-9, respectively). CHAPS {3-[(3-cholamidopro-
pyl)dimethylammonio]-1-propanesulfonate} was from Fluka
and AppliChem (ref. no. 26680 and A1099.0050 respec-
tively). EDTA (ethylenediaminetetraacetic acid), dithiothre-
itol (DTT), and glycerol were from Fluka (ref. no. 03620,
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43817, and 49780, respectively). G-Sepharose beads were
from GE Healthcare (ref. no. 17-0618-01). Dynabeads Pro-
tein G was from Life Technologies (ref. no. 10004D).
Nitrocellulose membranes was from Biorad (ref. no.
162-0115). MgCl2 was from Eurobio (ref. no. 018023).
EDTA-free Protease Inhibitor Cocktail Tablets were from
Roche Applied Science (ref. no. 1873580). SM-164 was
synthesized as described [29]. DSS (disuccinimidyl suberate)
was from Thermo Scientific Pierce (ref. no. 21555).
Buffers
The composition of phosphate buffered saline (PBS) is
116 mM NaCl, 10.4 mM Na2HPO4, 3.2 mM KH2PO4 (pH
7.4). The composition of the isotonic mitochondrial buffer
(MB) is 10 mM HEPES (pH 7.4), 210 mM mannitol, 70 mM
sucrose, 1 mM EDTA supplemented with one tablet of pro-
tease inhibitor cocktail per 50 ml. CHAPS lysis buffer is made
of 5 mM MgCl2, 137 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1 % CHAPS, 20 mM Tris-base, supplemented with
one tablet of protease inhibitor cocktail per 50 ml and adjus-
ted to pH 7.4 with HCl. MonoQ-c buffer is made of 70 mM b-
glycerophosphate, 0.5 % Triton X-100, 2 mM MgCl2, 1 mM
EGTA, 100 lM Na3VO4, 1 mM DTT, 20 lg/ml aprotinin
supplemented with one tablet of protease inhibitor cocktail per
50 ml. RIPA buffer contains 50 mM Tris base pH 8.0, 150
mM NaCl, 0.5 % deoxycholate, 1 % NP-40, 0.1% SDS sup-
plemented with one tablet of protease inhibitor cocktail per 50
ml.
Peptides
TAT and TAT-RasGAP317–326 are retro-inverso peptides
(i.e. synthesized with D-amino acids in the opposite
direction compared to the natural sequence). The TAT
moiety corresponds to amino acids 48–57 of the HIV TAT
protein (RRRQRRKKRG) and the RasGAP317–326 moiety
corresponds to amino acids 317–326 of the human RasGAP
protein (DTRLNTVWMW). These two moieties are sepa-
rated by two glycine linker residues in the TAT-Ras-
GAP317–326 peptide. The peptides were synthesized at the
department of biochemistry, University of Lausanne,
Switzerland, using FMOC technology, purified by HPLC
and tested by mass spectrometry.
Cell lines
U2OS, HCT116 were cultured in DMEM (Invitrogen, ref.
no. 61965) supplemented with 10 % heat-inactivated fetal
bovine serum (FBS; Invitrogen, ref. no. 10270-106) in 5 %
CO2 at 37 C. HeLa cells were cultured in RPMI (Invitro-
gen, ref. no. 61870) supplemented with 10 % heat-
inactivated FBS in 5 % CO2 at 37 C. Culturing of the cells
prior to performing the experiments described in this article
was performed in six-well plates by seeding 1000000 cells
(Figs. 1, 5b), 150,000 (Fig. 2, U2OS and HeLa cells),
200,000 (Fig. 2, HCT116 cells), or 250,000 cells (Figs. 5a,
6) in the wells 24 h before being treated as indicated in the
figures. HeLa cells were infected with LeGO-iT2 empty and
LeGO-iT2-Bcl-XL lentiviruses. Knock-out (KO) mouse
embryonic fibroblasts (MEFs) for Bcl-XL, Bcl-2, Mcl-1,
Bim, Bmf and Bid were transformed by infecting them with
a SV40 large T-encoding lentivirus [30, 31]. KO MEFs for
Bax, Bak, Bax/Bak and Bad were provided by the late Dr.
Stanley Korsmeyer. Culturing of the KO MEFs prior to
performing the experiments described in this article was
performed during 24 h in six-well plates by seeding 150,000
cells (Fig. 4). For starvation, cells were washed three times
with PBS and incubated for 24 h with medium lacking FBS.
TRAIL-induced apoptosis
Cells were incubated for 24 h with recombinant Flag–
TRAIL and 2 lg/ml anti-FLAG M2 antibody diluted in
culture medium.
UV illumination
Cells in culture dishes with the lid removed were UV-C-
illuminated using the UV lamp of a cell culture hood
(Fortuna from Scanlaf 1200) delivering an intensity of
0.25 J/m2 per second. The cells were then incubated for the
indicated periods of time in 5 % CO2 at 37 C.
Apoptosis quantitation
Cells were fixed in 2 % PFA and nuclei labeled with Hoechst
33342. Apoptotic cells (i.e. cells displaying a pycnotic
nucleus) were counted under a Nikon Eclipse TS100 micro-
scope. When apoptosis was assessed on a population of
transfected cells, only green cells (i.e. cells having incorpo-
rated the transfected plasmids) were counted.
Statistics
The statistical analyses were done with Microsoft Excel
(XP edition) using the unpaired Student’s t test. Signifi-
cance is indicated by an asterisk when P \ 0.05/n, where
P is the probability derived from the t test analysis and n is
the number of comparisons done (Bonferroni correction).
For Figs. 4, 6, and 8, the statistical test used was one-way
ANOVA followed by Bonferroni’s post hoc comparison
tests.
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Transfection
Cells were transfected using Lipofectamine 2000 (Gib-
coBRL, ref. no. 18324-012) according to the manufacturer’s
instructions. Briefly, the indicated plasmids, together with
0.5 lg of GFP-encoding plasmid, were diluted in 250 ll
DMEM without FBS. The amount of DNA used in the
transfection was kept constant to 4 lg by adding the appro-
priate quantities of the pcDNA3 empty vector. In parallel,
8 ll of lipofectamine were added to 250 ll of DMEM
without FBS and kept at room temperature for 5 min. Finally,
the DNA-containing medium was added drop by drop to the
lipofectamine-containing medium and the resulting 500 ll
mix was added to cells. Five hours later, cells were washed
once with fresh medium (DMEM supplemented with FBS)
and cultured for an additional 20 h period in the presence of
the treatments indicated in the figures.
Coimmunoprecipitation
7.5 9 105 U2OS and HeLa cells and 106 HCT116 cells were
seeded in 10 cm plates and the next day treated as shown in
the figures. Sixteen hours later, the cells were lysed in 300 ll
of 1 % CHAPS lysis buffer and 700 lg of the lysate proteins
were immunoprecipitated overnight with 1.5 lg of the 6A7
anti-Bax antibody. Immunoprecipitates were captured on
30 ll of protein G-Sepharose at 4 C for 2 h. Immunocom-
plexes were then washed three times in CHAPS lysis buffer
and eluted in 30 ll of 29 sample buffer (25 mM Tris-HCl
pH 7.5, 10 % glycerol, 6 % SDS, 0.02 % of bromophenol
blue and 100 mM DTT). The immunoprecipitates and 50 lg
of total cell lysates were separated by SDS-PAGE and then
transferred onto nitrocellulose membrane. The membranes
were blocked with TBS (20 mM Tris base, 130 mM NaCl,
pH 7.6) containing 0.1 % Tween 20 and 5 % non-fat milk
(TBS–TM) and incubated overnight at 4 C with a 1:1000
dilution of the N-20 anti-Bax antibody. Blots were then
washed with TBS containing 0.1 % Tween 20 (TBS-T),
incubated 1 h at room temperature with the appropriate
fluorophore-conjugated secondary antibody (1:5,000 dilu-
tion) and subsequently visualized with the Odyssey infrared
imaging system (LICOR Biosciences, Bad Homburg, Ger-
many). Bak immunoprecipitation was performed as descri-
bed above with the following modifications: 2,000 lg of the
lysate proteins were immunoprecipitated overnight with
1.5 lg of the Ab-2 anti-Bak antibody; immunoprecipitates
were captured with 15 ll of Dynabeads Protein G; and the
G23 anti-Bak antibody was used as the primary antibody for
immublotting.
Crosslinking of mitochondrial proteins
HeLa cells were harvested in PBS and centrifuged 10 min
at 1,0009g. Cells were then resuspended in isotonic MB,
broken by five passages through a 25G1 0.5- by 2.5-mm
needle fitted on a 2 ml syringe and centrifuged at
1,5009g for 5 min. This procedure was repeated twice and
supernatants from each step were pooled and centrifuged
5 min at 1,5009g. Supernatant was collected, centrifuged
5 min at 2,0009g and further centrifuged 10 min at
9,0009g. Pellet was resuspended in MB (100 ll), centri-
fuged 10 min at 7,0009g and the pellet, representing the
mitochondrial fraction, was finally resuspended in a vol-
ume of 85–100 ll of MB. Mitochondria (40 lg) were
incubated for 30 min at room temperature with
5 mM DSS. The reaction was stopped by addition of 1 M
Tris base pH 8 quenching buffer (final Tris concentration
of 20 mM). Mitochondria were centrifuged, resuspended in
30 ll RIPA lysis buffer and incubated on ice for 15 min.
After centrifugation at 16,0009g, the supernatant was
collected, mixed with 7.5 ll 5X loading buffer and ana-
lyzed by Western blot using the N-20 anti-Bax antibody.
Western blotting
Cells were lysed in 100 ll of monoQ-c buffer. Primary and
secondary antibodies were used at a 1:1000 and a 1:5000
dilution, respectively. Visualization of the bands was per-
formed using the Odyssey infrared imaging device and
software (Licor, Homburg, Germany). Protein levels were
quantitated using ImageJ software.
Antibodies
The anti-Puma rabbit polyclonal IgG antibody, the anti-Bid
rabbit polyclonal antibody, the anti-Bcl-XL rabbit polyclonal
IgG antibody, and the anti-caspase-3 rabbit polyclonal IgG
antibody were from Cell Signaling (ref. no. 4976, 2002, 2764
and 9665, respectively). The 6A7 anti-active Bax mouse
Fig. 1 Ability of TAT-RasGAP317–326 to sensitize tumor cells to
various cell death stimuli. a U2OS, HeLa and HCT116 were
subjected to UV-C illumination or treated during 24 h with various
apoptotic stimuli as indicated in the figure. Cells were then fixed and
apoptosis was counted by scoring pycnotic nuclei. C 30 lM cisplatin;
P 20 lM TAT-RasGAP317–326; TAT 20 lM TAT; UV-C 15 J/m
2
(U2OS), 25 J/m2 (HCT116 and HeLa); S starvation; CHX 10 lg/ml
CHX; TNFa: 1 ng/ml (U2OS and HeLa), 0.5 ng/ml (HCT116). The
results correspond to the mean ± 95 % CI of independent experi-
ments. The asterisks indicate a statistically significant difference
between cells treated or not with TAT-RasGAP317–326 in the presence
of the apoptogenic stimuli. b HeLa cells overexpressing Bcl-XL or not
were treated during 24 h with 20 lM TAT-RasGAP317–326 (P),
200 ng/ml TRAIL (TRAIL). Cells were then fixed and apoptosis was
counted by scoring pycnotic nuclei. Results correspond to the
mean ± 95 % CI of three independent experiments. The asterisk
denotes a statistical significant difference. c HeLa cells were infected
with empty virus or virus encoding Bcl-XL. Bcl-XL expression levels
were assessed by Western blotting
b
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monoclonal IgG1, the N-20 anti-total Bax rabbit polyclonal
IgG, and the G23 anti-total Bak rabbit polyclonal IgG anti-
bodies were from Santa Cruz (ref. no. sc-23959, sc-493 and
sc-832, respectively). The anti-Bcl-2 mouse monoclonal IgG1
antibody was from Upstate Biotechnology (ref. no. 05-341),
the Y37 anti-Mcl-1 rabbit monoclonal IgG antibody was from
Abcam (ref. no. ab32087), the 3C5 anti-Bim rat monoclonal
IgG2a antibody and the 1E1-1-10 anti-cIAP1 rat monoclonal
IgG2a antibody were from Enzo Life Sciences (ref. no. ALX-
804-527-C100 and ALX-803-335-C100, respectively). The
48/hILP/XIAP anti-XIAP mouse monoclonal IgG1 antibody
was from BD Biosciences (ref. no. 610762). The Ab-2 anti-
active Bak mouse monoclonal IgG2b antibody was from
Merck (ref. no. AM04). The mouse monoclonal anti-FLAG
M2 antibody was from Sigma (ref. no. F1804). Secondary
antibodies were goat anti-mouse IRDye800-conjugated anti-
body (Rockland, ref. no. 610-132-121), goat anti-rabbit Alexa
Fluor 680-conjugated antibody (Molecular Probes, ref. no.
A21109) and donkey anti-rabbit HRP-conjugated antibody
(Jackson ImmunoResearch, ref. no. 711-035-152).
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Plasmids
The pcDNA3 expression vector is from Invitrogen. pEGFP-C1
(Clontech) encodes the green fluorescent protein. Puma.cmv
(Origene) encodes human Puma. hTP53.dn3 (#703) encodes
human p53. It was generated by subcloning the 1,193 bp
EcoRI/BamHI fragment from hTP53.lti (#384; gift from
Richard Iggo) into pcDNA3 opened with the same two
enzymes. TRIP-PGK-IRESNEO-WHV (#350) is a lentiviral
vector bearing the neomycine resistance. SV40LargeTanti-
gen.pBABE-puro (#731) encodes the SV40 large T antigen
(Addgene; plasmid 13970). SV40LargeTantigen.lti-neo
(#738) similarly encodes the large T antigen but in a lentiviral
expression vector. It was constructed by subcloning the BamHI
2187 base pairs fragment of SV40LargeTantigen.pBABE-
puro into TRIP-PGK-IRESNEO-WHV (#350) opened with
the same enzyme. LeGO-iT2-Bcl-xL (#821) was constructed
by subcloning the 771 bp EcoRI fragment from hBcl-XL.dn3
(#274) into LeGO-iT2 (#809; Addgene: plasmid 27343). The
extension .lti indicates that the backbone is a lentiviral vector.
The extension .dn3 indicates that the backbone plasmid is
pcDNA3.
Results
Sensitizing activity of TAT-RasGAP317–326 to various
apoptotic stimuli
We demonstrated earlier that TAT-RasGAP317–326 sensi-
tizes several cancer cell lines to apoptosis induced by
genotoxins such as cisplatin and doxorubicin [8]. These
compounds are described to induce apoptosis mostly via the
intrinsic apoptosis pathway [13, 14]. To gain further insight
about the manner by which TAT-RasGAP317–326 exerts its
tumor sensitization effect, HeLa, U2OS, and HCT116 cancer
cells were treated with additional pro-apoptotic compounds.
Figure 1a shows that TAT-RasGAP317–326 favored cisplatin-
induced apoptosis in the three different cancer cell lines,
confirming earlier results [8, 28]. TAT-RasGAP317–326 sen-
sitized some, but not all, tumor cell lines to UV- or growth
factor deprivation-induced apoptosis, despite the fact that
these treatments can activate the intrinsic apoptotic pathway
[32, 33]. None of the tumor cell lines was sensitized by the
peptide to TNFa, an extrinsic pathway stimulator [34, 35] in
presence of CHX, a protein synthesis inhibitor that prevents
the expression of anti-apoptotic proteins that would other-
wise counteract the pro-apoptotic abilities of TNFa [36, 37].
These results suggest that TAT-RasGAP317–326 exerts a pro-
apoptotic role in conditions where the intrinsic cell death
pathway is engaged. However since HeLa and HCT116 are
type II cells [38, 39] (see also Fig. 1b), i.e. they need the
mitochondrial pathway to fully activate caspase-3 in
response to extrinsic death stimuli [40], it is unclear why
TAT-RasGAP317–326 does not have any sensitizing effect on
these cell lines when incubated with TNFa. One possibility is
that CHX prevents the expression of a protein that is targeted
by TAT-RasGAP317–326 to mediate its sensitization effect.
To test this hypothesis, we used another extrinsic pathway
stimulator, TNF-related apoptosis-inducing ligand (TRAIL)
[41]. Unlike TNFa ? CHX, the apoptotic response induced
by TRAIL was increased by TAT-RasGAP317–326 in HeLa
cells (Fig. 1b). These cells were confirmed to be type II cells
by the complete protection against TRAIL-induced apopto-
sis conferred by Bcl-XL over-expression (Fig. 1c).
TAT-RasGAP317–326 increases cisplatin-induced Bax
activation
Tumor cells sensitized by TAT-RasGAP317–326 to genotox-
in-induced apoptosis show increased caspase-3 activation
and more pronounced mitochondrial membrane depolar-
ization [28]. This suggests that the RasGAP-derived peptide
acts upstream of cytochrome c release from mitochondria.
Consequently, Bax, which is required for mitochondrial
outer membrane permeabilization, cytochrome c release,
and caspase activation [21], should be more activated by
genotoxins in the presence of TAT-RasGAP317–326. To study
the status of Bax activation, we performed immunoprecipi-
tation experiments with an antibody (Bax 6A7) that only
binds the active conformation of Bax. Figure 2a shows that
while TAT-RasGAP317–326 alone does not affect Bax acti-
vation, it increases cisplatin-induced Bax stimulation. Con-
sistent with these observations, the peptide did not induce
Fig. 2 TAT-RasGAP317–326 favors, in a caspase-independent man-
ner, the ability of cisplatin to activate Bax. a U2OS, HeLa and
HCT116 were treated for 16 h with 20 lM TAT-RasGAP317–326 and/
or with 30 lM of cisplatin as indicated in the figure. The cells were
then lysed and Bax was immunoprecipitated with an antibody (6A7)
that specifically recognizes the active conformation of Bax. Western
blots were revealed with the N-20 antibody recognizing all forms of
Bax. IP immunoprecipitate; TL total lysate; asterisk immunoglobulin
light chains. b HeLa cells were treated during 16 h with 20 lM TAT-
RasGAP317–326 and 30 lM cisplatin alone or in combination.
Mitochondria were isolated and cross-linked with DSS. Mitochondrial
proteins were extracted and Bax was analyzed by Western blotting.
c HCT116 were either left untreated or treated with the indicated
concentrations of cisplatin for 20 h, in the presence or in the absence
of the MX1013 pan-caspase inhibitor. The cells were then lysed and
the cleavage of caspase-3 was assessed by Western blotting. d U2OS
cells were processed as in panel A but in the presence or in the
absence of 10 lM MX1013. e HeLa cells were treated for 16 h with
20 lM TAT-RasGAP317–326 and/or with 30 lM of cisplatin as
indicated in the figure. The cells were then lysed and Bak was
immunoprecipitated with an antibody (Ab-2) that specifically recog-
nizes the active conformation of Bak. Western blots were revealed
with the G23 antibody recognizing all forms of Bak. IP immunopre-
cipitate; TL total lysate; asterisk immunoglobulin light chain; hash
non-specific band
b
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Bax oligomerization by itself but amplified cisplatin-
induced Bax oligomerization (Fig. 2b). Figure 2a (lower
blots) shows that neither cisplatin nor TAT-RasGAP317–326,
alone or in combination, alter total Bax cellular levels.
However, the amount of Bax associated with the mito-
chondria, either as monomers or dimers, is increased in cells
treated with cisplatin and TAT-RasGAP317–326 compared to
cells treated with cisplatin alone (Fig. 2b). It appears thus
that the RasGAP-derived peptide can facilitate cisplatin-
mediated Bax recruitment to the mitochondria.
There is evidence that caspase activation induces a
positive feedback loop to increase Bax activation and
cytochrome c release from the mitochondria [42]. To
determine if TAT-RasGAP317–326 modulates this feedback
loop, the experiment shown in Fig. 2a was repeated in the
presence of the MX1013 pan-caspase inhibitor [43, 44] that
efficiently blocks executioner caspase activity (Fig. 2c).
Figure 2d shows that caspase inhibition does not prevent
TAT-RasGAP317–326 from enhancing cisplatin-mediated
Bax activation. The role of Bak, the other Bcl-2 family
member involved in mitochondrial permeabilization was
also investigated but we did not observe modulation of
cisplatin-induced Bak activation by TAT- RasGAP317–326
(Fig. 2e).
TAT-RasGAP317–326 does not modulate Bcl-2 and IAP
family members
Bax activation is controlled by pro- and anti-apoptotic
members of the Bcl-2 family [19, 21]. Conceivably, TAT-
RasGAP317–326 could favor genotoxin-induced apoptosis
by increasing the levels of pro-apoptotic Bcl-2 family
members and/or decreasing the levels of the anti-apoptotic
members. However, the peptide did neither modulate the
expression of pro-apoptotic Bim, Puma and Bid proteins
nor the anti-apoptotic Bcl-XL, Bcl-2 and Mcl-1 proteins
(Fig. 3). Another possibility that could explain how TAT-
RasGAP317–326 favors apoptosis is inhibition of IAPs.
However, the peptide did not alter cellular levels of cIAP1,
cIAP2 and XIAP (Fig. 3). Therefore, modulation of the
expression of IAPs and Bcl-2 family members is not the
mechanism used by TAT-RasGAP317–326 to favor Bax
activation and apoptosis. However, this does not exclude
the possibility that the peptide affects the activity of these
proteins.
Targeted disruption of individual Bcl-2 family
members or IAPs does not prevent TAT-
RasGAP317–326-mediated tumor cell sensitization
Large T antigen-transformed MEFs lacking specific Bcl-2
family members were used to investigate the role of this
protein family in the capacity of TAT-RasGAP317–326 to
sensitize tumor cells to genotoxin-induced apoptosis.
MEFs are not cancer cells and hence are not susceptible to
TAT-RasGAP317–326-mediated genotoxin sensitization.
However, transforming MEFs with the SV40 large T
antigen renders them sensitive to the peptide [30]. Fig-
ure 4a shows that transformed MEFs lacking the pro-
apoptotic BH3-only Bid, Bim, Bmf, or Bad proteins or the
anti-apoptotic Bcl-XL, Bcl-2, or Mcl-1 proteins were effi-
ciently sensitized by TAT-RasGAP317–326 to cisplatin-
induced apoptosis. Furthermore, the pro-apoptotic family
members Bax and Bak, crucial for outer mitochondrial
membrane permeabilization are not individually required
to mediate TAT-RasGAP317–326 sensitization. As expected
[45], transformed MEFs lacking both Bax and Bak were
totally resistant to cisplatin-induced death.
We next examined the implication of cIAP1/2 and XIAP
in TAT-RasGAP317–326-mediated sensitization to cisplatin-
induced apoptosis. We used the SM-164 Smac mimetic to
induce cIAP1/2 degradation and XIAP inhibition [46]. In
presence of the Smac mimetic, the sensitization to cisplatin
induced by the peptide was not altered, despite strong
reduction in cIAP1 and cIAP2 levels, indicating that
cIAP1/2 and XIAP are not involved in TAT-Ras-
GAP317–326-mediated sensitization of cisplatin-induced
apoptosis.
TAT-RasGAP317–326 does not sensitize cells to Puma
over-expression
We previously hypothesized that an intact p53/Puma axis
was required for efficient genotoxin-induced apoptosis and
for TAT-RasGAP317–326 to favor genotoxin-induced
apoptosis in cancer cells [28]. We reasoned that if Puma is
necessary and sufficient for the sensitizing activity of the
RasGAP-derived peptide, ectopic expression of Puma
should render tumor cells sensitive to TAT-RasGAP317–326
in the absence of cisplatin. Figure 5a shows that trans-
fecting U2OS cells with amounts of Puma-encoding plas-
mids in the 0.5 to 3.5 lg range (open circles) led to similar
levels of Puma expression than obtained by treating the
cells with concentrations of cisplatin in the 2.5–30 lM
range (closed squares). However, TAT-RasGAP317–326
only sensitized cells incubated with cisplatin and not those
transfected with the Puma-encoding plasmids (Fig. 5b).
Puma is a p53 transcription target that may, once syn-
thesized, need p53 to exert its full pro-apoptotic actions
[47]. Figure 6 shows that ectopic expression of p53 in
U2OS cells induced apoptosis. However this was neither
modulated by Puma nor by TAT-RasGAP317–326. Taken
together these data suggest that TAT-RasGAP317–326 does
not directly amplify the DNA damage-induced p53/Puma
arm. Hence, even though cisplatin requires p53 and Puma
to induce apoptosis [28], this genotoxin may modulate
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other pro-apoptotic signals that are targeted by TAT-Ras-
GAP317–326 to induce cell death in cancer cells.
TAT-RasGAP317–326 affects long term survival
of cancer cells independently of p53
The above observation that the RasGAP-derived peptide
does not amplify the p53/Puma axis led us to reconsider the
implication of p53 in the TAT-RasGAP317–326-mediated
sensitization of cancer cells. Cells lacking an intact p53/
Puma axis show a drastically reduced apoptotic rate when
exposed to genotoxin treatment [28], but they may remain
sensitive to the drugs on longer term exposure. Indeed, Fig. 7
shows that the survival of either p53-positive or p53-nega-
tive HCT116 cells, tested by colony formation assay, was
reduced by cisplatin treatment to similar extent. Importantly,
TAT-RasGAP317–326 significantly augmented cisplatin-
mediated cell survival impairment in both cases (Fig. 7). It
was suggested, based on earlier observation that the HCT116
tumor cell line lacking either p53 or Puma did not undergo
more cisplatin-induced apoptosis in the presence of TAT-
RasGAP317–326 [28], that TAT-RasGAP317–326 required a
functional p53-Puma axis to exert its sensitizing function.
The data presented in Fig. 7 demonstrate that this initial
assumption is not correct. Presumably, the absence of p53 or
Puma by dramatically increasing the resistance of HCT116
cells to cisplatin-induced apoptosis [28] masks the sensitiz-
ing effect of the peptide in short-term experiments. Another
difference to take into account is the method used to evaluate
the sensitization to cisplatin. In previous report, sensitization
was evaluated using apoptosis-specific assays (i.e. scoring
cells with pycnotic nuclei). Here, HCT116 p53 KO cells
were shown to be sensitized to cisplatin using colony for-
mation assays. Apoptosis can affect the ability of cells to
form colonies but other forms of death (e.g. mitotic catas-
trophe, necrosis) can too. Hence the results shown in Fig. 7
indicate that TAT-RasGAP317–326 sensitizes tumors to sev-
eral types of cell death.
TAT-RasGAP317–326 sensitizes HCT116 cells
irrespectively of their Bax and Bak status
Recently, HCT116 cell lines lacking Bax and/or Bak were
generated [48]. We aimed to determine if Bax and Bak
were required for cisplatin-induced death and TAT-Ras-
GAP317–326-mediated sensitization in the HCT116 back-
ground as they were in the MEF background (see Fig. 4).
Bax and Bak status in HCT116 wild-type, single KOs and
double KO was first confirmed by Western blotting
(Fig. 8a). In contrast to MEFs, the absence of Bax and Bak
in HCT116 cells reduced, but did not abrogate the ability of
cisplatin to induce apoptosis (Fig. 8b) and, importantly, did
Fig. 3 TAT-RasGAP317–326
does not modulate Bcl-2 family
protein levels. U2OS, HCT116
and HeLa were treated as shown
in the figure for 22 h (TAT-
RasGAP317–326, 20 lM;
cisplatin, 30 lM). Cells were
then lysed and total protein
extracts were immunoblotted
with antibodies specific for the
indicated proteins (asterisk non-
specific band). cIAP2 was not
detected in HCT116 cells
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not prevent TAT-RasGAP317–326 from sensitizing these
cells to cisplatin-induced apoptosis. Using a colony for-
mation assay, it was found that cisplatin reduced more or
less to similar extents the survival of HCT116 cells
expressing or not Bax and Bak (Fig. 8c). The absence of
Bax and Bak did not alter the capacity of TAT-Ras-
GAP317–326 to favor cisplatin-mediated survival decrease.
These results indicate that apoptosis and cell death induced
by genotoxins such as cisplatin can occur in the absence of
a functional mitochondrial apoptotic pathway (i.e. in the
absence of Bax and Bak in HCT116 cells) and that these
modes of death can be augmented by TAT-RasGAP317–326.
Discussion
This study provides advances in the understanding on the
mode of action of TAT-RasGAP317–326. It shows that this
peptide enhances cisplatin-induced Bax activation. The
RasGAP-derived peptide can therefore positively modulate
Fig. 4 Role of individual Bcl-2
family proteins in TAT-
RasGAP317–326-mediated
sensitization to cisplatin-
induced apoptosis. a SV40-
transformed MEFs lacking the
indicated Bcl-2 family proteins
were treated as indicated in the
figure for 22 h. Cells were then
fixed and apoptosis was counted
by scoring pycnotic nuclei. The
results correspond to the mean
±95 % CI of at least three
independent experiments. The
asterisks indicate a statistically
significant difference (as
assessed by unpaired t test
between cells treated or not with
TAT-RasGAP317–326 in the
presence cisplatin). b HeLa
cells were treated for 16 h with
20 lM TAT-RasGAP317–326
(P) and/or with 30 lM of
cisplatin (C) in the presence or
in the absence of 100 nM Smac
mimetic (SM) as indicated in
the figure. Cells were then fixed
and apoptosis was determined
by scoring pycnotic nuclei. The
results correspond to the mean
±95 % CI of three independent
experiments. c Cells were lysed
and cIAP1 and cIAP2
expression controlled by
Western blotting
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the intrinsic apoptotic pathway activated by genotoxins. But
the ability of TAT-RasGAP317–326 to favor genotoxin-acti-
vated tumor cell death is not limited to the intrinsic apoptotic
pathway because i) cisplatin-induced apoptosis and TAT-
RasGAP317–326-mediated sensitization can occur in cells
lacking Bax and Bak and ii) tumor cells lacking p53 can be
sensitized by the RasGAP-derived peptide to die by an
apparently non-apoptotic form of cell death. Hence, TAT-
RasGAP317–326-mediated tumor cell sensitization to geno-
toxins can occur independently of Bax, Bak, and p53
through a death pathway that remains to be clarified.
Increased Bax stimulation in the context of TAT-
RasGAP317–326-mediated sensitization
Bax and Bak are Bcl-2 family members the activation and
oligomerization of which induce permeabilization of the
mitochondrial outer membrane, resulting in the release of
cytochrome c [21]. This study shows that TAT-Ras-
GAP317–326 increases genotoxin-induced Bax activation.
However, how this augmentation is accomplished remains
unclear. First, the ability of TAT-RasGAP317–326 to increase
genotoxin-induced Bax activation did not require caspase
activation (Fig. 2). Therefore, the peptide does not amplify a
positive feedback loop on Bax activation induced by the
stimulation of caspases following cytochrome c release [42].
Second, Bax activation does not result from a peptide-
induced balance shift between the expression levels of pro-
and anti-apoptotic Bcl-2 family members. Indeed, the protein
levels of Bcl-2, Bcl-XL, Mcl-1, Bim, Puma, and Bid were not
modulated by TAT-RasGAP317–326 (Fig. 3). Moreover, the
expression of IAPs was not modified by the RasGAP-derived
peptide. However, this does not exclude the possibility that
the peptide affects the activity of these proteins. In addition,
all the Bcl-2 family proteins we have tested (Bcl-2, Bcl-XL,
Mcl-1, Bim, Bid, Bmf and Bad) were shown to be individ-
ually dispensable for the sensitizing activity of the peptide.
Fig. 5 Puma expression per se does not render tumor cells sensitive
to TAT-RasGAP317–326. a U2OS were treated with increasing
concentrations of cisplatin or transfected with the indicated amounts
of a Puma-encoding plasmid. Puma protein levels were then
determined by quantitative Western blotting. b U2OS cells were
treated as in panel a and then incubated or not with TAT-
RasGAP317–326 (20 lM) for 22 h. Apoptosis was then determined.
Results correspond to the mean ± 95 % CI of three independent
experiments. hash indicates a statistically significant difference
between cells incubated or not with TAT-RasGAP317–326 at given
doses of cisplatin. dollar denotes significant differences to the ‘‘0 lM
cisplatin’’ condition
Fig. 6 Ectopic expression of p53 and Puma does not render cancer
cells sensitive to TAT-RasGAP317–326. U2OS were transfected with
the indicated plasmids and treated or not with 20 lM of TAT-
RasGAP317–326 for 22 h. Apoptosis was then determined. Results
correspond to the mean ± 95 % CI of four independent experiments.
NS no statistically significant difference
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This suggests that these proteins are not direct or indirect
targets of TAT-RasGAP317–326. However, the possibility that
the RasGAP-derived peptide targets several Bcl-2 family
members, which compensate each other when one is absent to
mediate the sensitizing action of the peptide, cannot be
excluded at the present time. Furthermore, HCT116 Bax KO
cells were found to be sensitized to genotoxin-induced death.
This indicates that TAT-RasGAP317–326-mediated sensitiza-
tion is not strictly restricted to increased Bax activation.
TAT-RasGAP317–326-mediated sensitization
independently of Bax and Bak (and p53)
In contrast to MEFs, HCT116 cells lacking Bax and Bak
can still undergo genotoxin-induced apoptosis and this cell
death response can be increased by TAT-RasGAP317–326.
Moreover, HCT116 cells lacking p53, despite being greatly
compromised in their ability to apoptose in response to
genotoxins, as evidenced by their resistance to pycnosis,
are nevertheless more efficiently killed in long-term sur-
vival experiments (colony-formation assays) by genotoxins
when incubated with the RasGAP-derived peptide. Thus,
TAT-RasGAP317–326 has the capacity to favor non-mito-
chondrial forms of cell death.
Recent findings in non-small cell lung cancer showed that
Bax and Bak can be dispensable for cisplatin-induced
apoptosis [49]. In this study, using cisplatin-sensitive and
cisplatin-resistant cell lines lacking Bax and Bak, it was
shown that cisplatin-induced apoptosis may rely on caspase-
8 activation in an acid sphingomyelinase and Fas-associated
death domain (FADD)-dependent manner. Incidentally, it is
also noticed that Bax/Bak DKO MEFs were found to be
totally resistant to cisplatin-induced apoptosis in line with
the data presented in Fig. 4. One could hypothesize that
apoptosis in Bax/Bak DKO HCT116 cells is mediated
through caspase-8 activation and that TAT-RasGAP317–326
increases this response. The implication of caspase-8 in
TAT-RasGAP317–326 cancer cell sensitization remains to be
defined however.
The present report also clarifies the role played by p53
(and Puma) in TAT-RasGAP317–326-mediated sensitization
of tumor cells to genotoxin-induced apoptosis. Interpreta-
tions of earlier work were that TAT-RasGAP317–326
required a functional p53/Puma axis to favor apoptosis of
cisplatin-stimulated tumor cells [28]. We therefore
hypothesized that reproducing expression of p53 and Puma
in cancer cells, which occurs when cells are treated with
cisplatin, would render them sensitive to TAT-Ras-
GAP317–326. However, this proved not to be the case
(Figs. 5, 7). Moreover, tumor cells lacking p53, even
though highly resistant to cisplatin-induced apoptosis in
short-term experiments [28], were nevertheless less able to
survive long-term cisplatin treatment when co-treated with
TAT-RasGAP317–326 (Fig. 7). This indicates that the Ras-
GAP-derived peptide does not require p53 to exert its
tumor sensitization activity. Hence, p53 and Puma are not
Fig. 7 TAT-RasGAP317–326
sensitizes cancer cells to
cisplatin-induced cell death
irrespectively of their p53
status. Wild-type HCT116 and
p53-/- HCT116 were treated
with 1 lM cisplatin in the
presence or in the absence of
20 lM TAT-RasGAP317–326
(P) or 20 lM TAT for 3 days.
Culture medium was then
replaced with fresh medium and
following an additional 10-day
period the number of colonies
was recorded. N/T untreated.
The results correspond to the
mean ± 95 % CI of at least
three independent experiments.
The asterisks indicate a
statistically significant
difference between cisplatin-
treated cells incubated or not
with TAT-RasGAP317–326
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targets of TAT-RasGAP317–326. The apparent requirement
of p53 and Puma for the genotoxin sensitizing function of
the peptide in short-term apoptosis assays most likely
results from the fact that genotoxins inefficiently induce
apoptosis of tumor cells lacking a functional p53/Puma
axis [50]. In other words, the absence of TAT-Ras-
GAP317–326-mediated sensitization observed in p53- or
Puma-negative cells merely reflects the fact these cells
cannot properly undergo genotoxin-induced apoptosis.
Measuring cell death in short-term assays (e.g. within the
first 24 h of treatment) might lead to an underestimation of
the killing potential of genotoxins, as long-term cell sur-
vival is not taken into account. This may particularly be the
case in cells bearing mutations in apoptosis-controlling
proteins. Tumor cells lacking p53 can bypass the primary
apoptotic decision, which takes place shortly after the
administration of an apoptotic stimulus, and undergo sev-
eral cell divisions before dying. This can occur either by
p53-independent apoptosis or as a result of mitotic catas-
trophe or necrotic cell death [51]. The observation that
Fig. 8 TAT-RasGAP317–326
sensitizes HCT116 cancer cells
to cisplatin-induced cell death
irrespectively of their Bax and
Bak status. a Bax and Bak
expression was assessed by
Western blotting in wild-type
(WT) HCT116, HCT116 Bak
KO, HCT116 Bax KO and
HCT116 Bax/Bak DKO cells
(asterisk non-specific band).
b WT HCT116 and HCT116
Bax/Bak DKO cells were
treated during 24 h with 20 lM
TAT-RasGAP317–326 (P),
30 lM cisplatin (C). Cells were
then fixed and apoptosis was
assessed by scoring pycnotic
nuclei. Results correspond to the
mean ± 95 % CI of three
independent experiments. The
asterisk denotes a statistical
significant difference. c The
indicated HCT116 cell lines
were treated with 2 lM
cisplatin in the presence or in
the absence of 20 lM TAT-
RasGAP317–326 (P) or 20 lM
TAT for 3 days. Culture
medium was then replaced with
fresh medium and following an
additional 10-day period the
number of colonies was
recorded. N/T untreated. The
results correspond to the
mean ± 95 % CI of four
independent experiments. The
asterisks indicate a statistically
significant difference between
cisplatin-treated cells incubated
or not with TAT-RasGAP317–326
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TAT-RasGAP317–326, in combination with cisplatin, redu-
ces the viability of p53-negative tumor cells demonstrates
that this peptide can also positively reinforces p53-inde-
pendent cell death mechanism(s) that occur in a more
delayed manner compared to short-term apoptosis.
Earlier reports indicate that cisplatin [49] and TRAIL
(reviewed in [52]) induce caspase-8 activation. Since the
present work shows that TAT-RasGAP317–326 sensitizes
tumor cells to cisplatin and TRAIL-induced apoptosis, it
raises the possibility that the peptide acts at the level of
caspase-8 or of a caspase 8-containing complex. The
activation of caspase-8 is modulated by several proteins,
for instance positively by FADD and negatively by cellular
FADD-like interleukin-1b–converting enzyme (FLICE)-
like inhibitory protein (cFLIP) [53]. Hypothetically, TAT-
RasGAP317–326 could favor FADD activity to activate
caspase-8 or the peptide could neutralize the cFLIP
inhibitory effect. Further work is now needed to dissect the
role played by caspase-8 and its binding partners in the
tumor sensitizing activities of TAT-RasGAP317–326.
Acknowledgments We thank Dr. Pascal Meier (Institute of Cancer
Research: Royal Cancer Hospital, London, UK) for the generous gift
of IAP-specific antibodies; Dr. David Huang (Walter and Eliza Hall
Institute of Medical Research, Parkville Victoria, Australia) for pro-
viding MEFs lacking specific Bcl-2 family members; Dr. Richard J.
Youle (Biochemistry Section, Surgical Neurology Branch, National
Institute of Neurological Disorders and Stroke, National Institutes of
Health, Bethesda, MD, USA) for HCT116 Bak KO and HCT116 Bax/
Bak DKO and Dr. Pascal Schneider (University of Lausanne,
De´partement de Biochimie, Lausanne, Switzerland) for Flag–TRAIL.
This work was supported by Swiss National Science Foundation grant
31003A_141242 (to CW). The funder had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
Conflict of interest CW is a coinventor of the TAT-RasGAP317–326
compound as a genotoxin sensitizer (patent owned by the University
of Lausanne) and may receive royalties from patent licensing if the
compound is commercialized. Patent numbers and dates are WO
2005000887 (30.6.2003) and WO 2010097720 (30.1.2009). The other
authors declare that they have no conflict of interest.
References
1. Michod D, Widmann C (2007) DNA-damage sensitizers: poten-
tial new therapeutical tools to improve chemotherapy. Crit Rev
Oncol Hematol 63:160–171
2. Schmitt E, Parcellier A, Gurbuxani S et al (2003) Chemosensi-
tization by a non-apoptogenic heat shock protein 70-binding
apoptosis-inducing factor mutant. Cancer Res 63:8233–8240
3. Schmitt E, Maingret L, Puig PE et al (2006) Heat shock protein
70 neutralization exerts potent antitumor effects in animal models
of colon cancer and melanoma. Cancer Res 66:4191–4197
4. Taylor RC, Cullen SP, Martin SJ (2008) Apoptosis: controlled
demolition at the cellular level. Nat Rev Mol Cell Biol 9:231–241
5. Fulda S, Wick W, Weller M, Debatin KM (2002) Smac agonists
sensitize for Apo2L/T. Nat Med 8:808–815
6. Yang L, Mashima T, Sato S et al (2003) Predominant suppression
of apoptosome by inhibitor of apoptosis protein in non-small cell
lung cancer H460 cells: therapeutic effect of a novel polyargi-
nine-conjugated Smac peptide. Cancer Res 63:831–837
7. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran
PG (2004) A small molecule Smac mimic potentiates TRAIL-
and TNFa-mediated cell death. Science 305:1471–1474
8. Michod D, Yang JY, Chen J, Bonny C, Widmann C (2004) A
RasGAP-derived cell permeable peptide potently enhances geno-
toxin-induced cytotoxicity in tumor cells. Oncogene 23:8971–8978
9. Heitz F, Morris MC, Divita G (2009) Twenty years of cell-
penetrating peptides: from molecular mechanisms to therapeutics.
Br J Pharmacol 157:195–206
10. Michod D, Annibaldi A, Schaefer S, Dapples C, Rochat B,
Widmann C (2009) Effect of RasGAP N2 fragment-derived
peptide on tumor growth in mice. J Natl Cancer Inst 101:828–832
11. Pittet O, Petermann D, Michod D et al (2007) Effect of the TAT-
RasGAP317–326 peptide on apoptosis of human malignant meso-
thelioma cells and fibroblasts exposed to meso-tetra-hydro-
xyphenyl-chlorin and light. J Photochem Photobiol, B 88:29–35
12. Barras D, Lorusso G, Ruegg C, Widmann C (2013) Inhibition of
cell migration and invasion mediated by the TAT-RasGAP317–326
peptide requires the DLC tumor suppressor. Oncogene. doi:10.
1038/onc.2013.465
13. Debatin KM, Poncet D, Kroemer G (2002) Chemotherapy: targeting
the mitochondrial cell death pathway. Oncogene 21:8786–8803
14. Kaufmann SH, Earnshaw WC (2000) Induction of apoptosis by
cancer chemotherapy. Exp Cell Res 256:42–49
15. Fulda S, Debatin KM (2006) Extrinsic versus intrinsic apoptosis
pathways in anticancer chemotherapy. Oncogene 25:4798–4811
16. Zhou BB, Bartek J (2004) Targeting the checkpoint kinases:
chemosensitization versus chemoprotection. Nat Rev Cancer
4:216–225
17. Shiloh Y (2003) ATM and related protein kinases: safeguarding
genome integrity. Nat Rev Cancer 3:155–168
18. Michalak E, Villunger A, Erlacher M, Strasser A (2005) Death
squads enlisted by the tumour suppressor p53. Biochem. Biophys.
Res. Commun. 331:786–798
19. Youle RJ, Strasser A (2008) The BCL-2 protein family: opposing
activities that mediate cell death. Nat Rev Mol Cell Biol 9:47–59
20. Green DR, Kroemer G (2004) The pathophysiology of mito-
chondrial cell death. Science 305:626–629
21. Chipuk JE, Green DR (2008) How do BCL-2 proteins induce
mitochondrial outer membrane permeabilization? Trends Cell
Biol 18:157–164
22. Galonek HL, Hardwick JM (2006) Upgrading the BCL-2 net-
work. Nat Cell Biol 8:1317–1319
23. Chen C, Cui J, Zhang W, Shen P (2007) Robustness analysis
identifies the plausible model of the Bcl-2 apoptotic switch.
FEBS Lett 581:5143–5150
24. Villunger A, Labi V, Bouillet P, Adams J, Strasser A (2011) Can
the analysis of BH3-only protein knockout mice clarify the issue
of ‘direct versus indirect’ activation of Bax and Bak? Cell Death
Differ 18:1545–1546
25. Willis SN, Adams JM (2005) Life in the balance: how BH3-only
proteins induce apoptosis. Curr Opin Cell Biol 17:617–625
26. Giam M, Huang DC, Bouillet P (2008) BH3-only proteins and their
roles in programmed cell death. Oncogene 27(Suppl 1):S128–S136
27. Martinou JC, Youle RJ (2011) Mitochondria in apoptosis: Bcl-2
family members and mitochondrial dynamics. Dev Cell
21:92–101
28. Michod D, Widmann C (2007) TAT-RasGAP317–326 requires p53
and PUMA to sensitize tumor cells to genotoxins. Mol Cancer
Res 5:497–507
29. Sun H, Nikolovska-Coleska Z, Lu J et al (2007) Design, synthesis,
and characterization of a potent, nonpeptide, cell-permeable,
732 Apoptosis (2014) 19:719–733
123
bivalent Smac mimetic that concurrently targets both the BIR2 and
BIR3 domains in XIAP. J Am Chem Soc 129:15279–15294
30. Annibaldi A, Dousse A, Martin S, Tazi J, Widmann C (2011)
Revisiting G3BP1 as a RasGAP binding protein: sensitization of
tumor cells to chemotherapy by the RasGAP 3127-326 sequence
does not involve G3BP1. PLoS One 6:e29024
31. Chen L, Willis SN, Wei A et al (2005) Differential targeting of
prosurvival Bcl-2 proteins by their BH3-only ligands allows
complementary apoptotic function. Mol Cell 17:393–403
32. Bialik S, Cryns VL, Drincic A et al (1999) The mitochondrial
apoptotic pathway is activated by serum and glucose deprivation
in cardiac myocytes. Circ Res 85:403–414
33. Dunkern TR, Fritz G, Kaina B (2001) Ultraviolet light-induced
DNA damage triggers apoptosis in nucleotide excision repair-
deficient cells via Bcl-2 decline and caspase-3/-8 activation.
Oncogene 20:6026–6038
34. Hengartner MO (2000) The biochemistry of apoptosis. Nature
407:770–776
35. Walczak H, Krammer PH (2000) The CD95 (APO-1/Fas) and the
TRAIL (APO-2L) apoptosis systems. Exp Cell Res 256:58–66
36. Muppidi JR, Tschopp J, Siegel RM (2004) Life and death deci-
sions: secondary complexes and lipid rafts in TNF receptor
family signal transduction. Immunity 21:461–465
37. Lavrik I, Golks A, Krammer PH (2005) Death receptor signaling.
J Cell Sci 118:265–267
38. Ozoren N, El-Deiry WS (2002) Defining characteristics of types I
and II apoptotic cells in response to TRAIL. Neoplasia 4:551–557
39. Mandal M, Maggirwar SB, Sharma N, Kaufmann SH, Sun SC,
Kumar R (1996) Bcl-2 prevents CD95 (Fas/APO-1)-induced deg-
radation of lamin B and poly(ADP-ribose) polymerase and restores
the NF-kappaB signaling pathway. J Biol Chem 271:30354–30359
40. Scaffidi C, Fulda S, Srinivasan A et al (1998) Two CD95 (APO-
1/Fas) signaling pathways. EMBO J 17:1675–1687
41. Wiley SR, Schooley K, Smolak PJ et al (1995) Identification and
characterization of a new member of the TNF family that induces
apoptosis. Immunity 3:673–682
42. Lakhani SA, Masud A, Kuida K et al (2006) Caspases 3 and 7:
key mediators of mitochondrial events of apoptosis. Science
311:847–851
43. Jaeschke H, Farhood A, Cai SX, Tseng BY, Bajt ML (2000)
Protection against TNF-induced liver parenchymal cell apoptosis
during endotoxemia by a novel caspase inhibitor in mice. Toxicol
Appl Pharmacol 169:77–83
44. Yang W, Guastella J, Huang JC et al (2003) MX1013, a dipeptide
caspase inhibitor with potent in vivo antiapoptotic activity. Br J
Pharmacol 140:402–412
45. Wei MC, Zong WX, Cheng EH et al (2001) Proapoptotic BAX
and BAK: a requisite gateway to mitochondrial dysfunction and
death. Science 292:727–730
46. Lu J, Bai L, Sun H et al (2008) SM-164: a novel, bivalent Smac
mimetic that induces apoptosis and tumor regression by concur-
rent removal of the blockade of cIAP-1/2 and XIAP. Cancer Res
68:9384–9393
47. Chipuk JE, Bouchier-Hayes L, Kuwana T, Newmeyer DD, Green
DR (2005) PUMA couples the nuclear and cytoplasmic proa-
poptotic function of p53. Science 309:1732–1735
48. Wang C, Youle RJ (2012) Predominant requirement of Bax for
apoptosis in HCT116 cells is determined by Mcl-10s inhibitory
effect on Bak. Oncogene 31:3177–3189
49. Paul I, Chacko AD, Stasik I et al (2012) Acquired differential
regulation of caspase-8 in cisplatin-resistant non-small-cell lung
cancer. Cell Death Dis 3:e449
50. Villunger A, Michalak EM, Coultas L et al (2003) p53- and drug-
induced apoptotic responses mediated by BH3-only proteins
puma and noxa. Science 302:1036–1038
51. Ma Y, Conforti R, Aymeric L et al (2011) How to improve the
immunogenicity of chemotherapy and radiotherapy. Cancer
Metastasis Rev 30:71–82
52. Merino D, Lalaoui N, Morizot A, Solary E, Micheau O (2007)
TRAIL in cancer therapy: present and future challenges. Expert
Opin Ther Targets 11:1299–1314
53. Oberst A, Green DR (2011) It cuts both ways: reconciling the
dual roles of caspase 8 in cell death and survival. Nat Rev Mol
Cell Biol 12:757–763
Apoptosis (2014) 19:719–733 733
123
